You are here: Industry Insights > Keytruda

News List

Summary of Immune Checkpoint Inhibitor Combined with ADC Yefenghong/PharmaSources
July 25, 2023
With the maturity of ADC technology, the combined scheme of IO and ADC is showing a therapeutic potential.
PK Hengrui! New indication of Merck's PD-1 monoclonal antibody Keytruda esophageal cancer is about to be approved in China CPhI.CN
June 17, 2020
New indication of Merck's PD-1 monoclonal antibody Keytruda esophageal cancer is about to be approved in China
Early research suggests Merck cancer drug may target dormant HIV ExpressPharma
January 29, 2022
Antiretroviral treatments now allow many HIV patients to lead normal lives, but the drugs do not completely remove the virus from the body
Merck’s Keytruda obtains EC approval as adjuvant therapy for kidney cancer Pharmaceutical-Technology
January 28, 2022
In a Phase III trial, Keytruda lowered the disease recurrence or mortality risk by 32% versus placebo.
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer prnasia
January 11, 2022
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD...
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer pharmatimes
January 07, 2022
With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK.
FDA grants Fast Track status to Genprex’s drug for NSCLC treatment Pharmaceutical-Technology
January 05, 2022
In preclinical studies, Reqorsa plus Keytruda were found to be efficient versus Keytruda alone in boosting survival.
Japan approves Keytruda plus Lenvima combination for endometrial cancer treatment drugs
December 28, 2021
the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Keytruda plus Lenvima combination to treat endometrial carcinoma.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Renal Cell Carcinoma AmericanPharmaceuticalReview
December 20, 2021
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA...
SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors B3Cnewswire
December 09, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page